How I treat MDS after hypomethylating agent failure.
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2018-03-785915
Abstract: Hypomethylating agents (HMA) azacitidine and decitabine are standard of care for myelodysplastic syndrome (MDS). Response to these agents occurs in ∼50% of treated patients, and duration of response, although variable, is transient. Prediction of response… read more here.
Keywords: hypomethylating agent; hma failure; treat mds; mds hypomethylating ... See more keywords
Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia.
Sign Up to like & getrecommendations! Published in 2018 at "Blood advances"
DOI: 10.1182/bloodadvances.2018015529
Abstract: Hypomethylating agent (HMA) failure in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) carries a poor prognosis with limited treatment options. Although intensive, remission induction chemotherapy is often used subsequently, in particular to bridge to… read more here.
Keywords: hypomethylating agent; hma failure; myeloid leukemia; acute myeloid ... See more keywords
Response to induction or hypomethylating agent therapy among patients with myeloproliferative neoplasms progressing to accelerated or leukemic phase.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e18561
Abstract: e18561Background: Post-myeloproliferative neoplasm (MPN) acute myeloid leukemia (AML) and accelerated phase disease (AP) are associated with poor outcomes; the optimal management of these patients ... read more here.
Keywords: therapy among; hypomethylating agent; among patients; agent therapy ... See more keywords
Hypomethylating agent (HMA) treatment as a bridge to allogeneic hematopoietic cell transplantation (HCT) for relapsed/refractory acute myeloid leukemia (RR-AML).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.7033
Abstract: 7033Background: Outcomes for patients (pts) with RR-AML are poor, with limited treatment options. Salvage HMA therapy has been explored for RR-AML but is often considered palliative. We examined re... read more here.
Keywords: treatment bridge; hypomethylating agent; treatment; hma treatment ... See more keywords
Methylation profiling of hypomethylating agent response and treatment failure in pediatric and young adult MDS/AML.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e22502
Abstract: e22502Background: Hypomethylating agents (HMAs) have favorable toxicity profiles and anti-leukemia activity in adult AML/MDS. We previously reported similar activity in eight pediatric patients (Ph... read more here.
Keywords: profiling hypomethylating; adult; hypomethylating agent; methylation profiling ... See more keywords
Integrative Analyses Reveal the Anticancer Mechanisms and Sensitivity Markers of the Next-Generation Hypomethylating Agent NTX-301
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15061737
Abstract: Simple Summary We thoroughly investigated the experimental and preclinical efficacy of the novel hypomethylating agent (HMA) NTX-301 through comparative analyses with conventional HMAs. By performing multiomics data analyses, we demonstrated the mechanisms of action underlying… read more here.
Keywords: sensitivity; ntx 301; hypomethylating agent; efficacy ... See more keywords